Browse Studies — Arctuva

Observational

An Early Feasibility Study Assessing Treatment of Pulmonary Hypertension Using the Aria CV Pulmonary Hypertension System

This prospective study is a multi-center early feasibility study assessing the safety and performance of the Aria CV Pulmonary Hypertension System in patients …

Pulmonary Arterial HypertensionPulmonary HypertensionRight Heart Dysfunction

Estimated

~$10 – $8,750

Aria CV, IncNCT04555161

Phase 2

A Phase 2 Open-label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Sotatercept (MK-7962) in Children From 1 to Less Than 18 Years of Age With PAH on Standard of Care

The primary objectives of the study are to evaluate the safety and tolerability, and pharmacokinetics (PK) of sotatercept over 24 weeks of treatment in childre…

Pulmonary Arterial Hypertension

Estimated

~$10 – $8,750

Merck Sharp & Dohme LLCNCT05587712

Risk and Resilience in Pulmonary Arterial Hypertension and Genetically Susceptible Individuals

Pulmonary arterial hypertension (PAH) is a severe disease with a delayed diagnosis and markedly elevated mortality. High-risk populations, such as those with k…

Idiopathic Pulmonary Arterial HypertensionHeritable Pulmonary Arterial HypertensionUnaffected Mutation Carriers: Healthy Participants With a Known BMPR2 Gene Mutation and Normal Pulmonary Pressure and RV Function on Echo+1 more

Estimated

~$10 – $750

Vanderbilt University Medical CenterNCT05584722